Aldosterone in Heart Disease
- Anastasia S. Mihailidou
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Numerous studies have now shown that sustained elevation of aldosterone levels induces cardiovascular damage independent from its effects on regulation of renal sodium and blood pressure. Increased aldosterone and cortisol levels in patients with heart failure independently predict the risk of mortality. Over the past decade, there has been increased interest in identifying the role of the receptor for aldosterone, the mineralocorticoid receptor (MR), following the results from the large clinical heart failure trials that showed low doses of MR antagonists reduced morbidity and mortality in heart failure and myocardial infarction, even though plasma levels of aldosterone were in the physiologic range. The mechanism for this cardioprotective action remains to be defined, although changes in the redox state have been shown to play a key role in MR-mediated cardiac damage. This review will highlight some of these studies and provide an update on the action of aldosterone in heart disease.
- Simpson SA, Tait JF, Wettstein A, et al. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia. 1953;9:333–5. CrossRef
- Beygui F, Collet J-P, Benoliel J-J, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604–10. CrossRef
- Beygui F, Montalescot G, Vicaut E, et al. Aldosterone and long-term outcome after myocardial infarction: A substudy of the French nationwide Observatoire sur la Prise en charge hospitalière, l’Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157(4):680–7. CrossRef
- Weir RAP, Tsorlalis IK, Steedman T, et al. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Failure. 2011;13:1305–13. CrossRef
- Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709–16. CrossRef
- Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30. CrossRef
- Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45. CrossRef
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17. CrossRef
- Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21. CrossRef
- •• Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. This study shows that mineralocorticoid receptor (MR) antagonists may delay the progression of heart failure in patients with mild heart failure symptoms (NYHA II) and has affirmed the important role of MR blockade across both severe and mild systolic heart failure. CrossRef
- Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730–6. CrossRef
- Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 1998;19:1552–63. CrossRef
- Güder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754–61. CrossRef
- Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A–6A. CrossRef
- Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578–80. CrossRef
- Wang Q, Clement S, Gabbiani G. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol. 2004;286:F1178–84. CrossRef
- •• Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case control study. J Clin Endocrinol Metab. 2011;96:2813–2820. This important clinical study extends the results from the experimental animal models to humans and confirms an interaction between aldosterone and salt status as a strong determinant of cardiac damage. CrossRef
- Rocha R, Rudolph AE, Frierdich GE. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802–10.
- Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81. CrossRef
- •• Shibata S, Mu S, Kawarazaki H, Muraoka K., et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233–3243. This important study provides the mechanism for the synergistic action between high salt and aldosterone in renal damage & hypertension. CrossRef
- Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370–6. CrossRef
- • Nagase M, Ayuzawa N, Kawarazaki W, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 2012 Jan 9 (Epub ahead of print). This paper provides preliminary evidence for reactive oxygen species–mediated MR activation and cardiac damage.
- Noble D. Ionic mechanisms determining the timing of ventricular repolarization: significance for cardiac arrhythmias. Ann N Y Acad Sci. 1992;644:1–22. CrossRef
- Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah J-P, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;11:3025–33. CrossRef
- Pieske B, Maier LS, Piacentino V, et al. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002;106:447–53. CrossRef
- Mihailidou AS, Bungaard H, Mardini M, et al. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na + -K + pump. Circ Res. 2000;86:37–42.
- Komentiani P, Li J, Gnudi L, et al. Multiple signal transduction pathways link Na+/K + -ATPase to growth-related genes in cardiac myocytes. J Biol Chem. 1998;24:15249–56. CrossRef
- Kent RL, Hoober K, Cooper IV G. Load responsiveness of protein synthesis in adult mammalian myocardium: role of cardiac deformation linked to sodium influx. Circ Res. 1989;64:74–85.
- Huang L, Kometiani P, Xie Z. Differential regulation of Na/K-ATPase a-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. J Mol Cell Cardiol. 1997;29:3157–67. CrossRef
- •Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191–202. This study shows that plasma aldosterone levels measured in patients with coronary artery disease without MI or heart failure predict future cardiovascular events. CrossRef
- Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. J Am Coll Cardiol. 2002;40:1596–601. CrossRef
- • Le TYL, Ashton A, Mardini M, Funder JW, Mihailidou AS. Cardioprotective action of mineralocorticoid receptor antagonists during experimental myocardial infarction: role of Apoptosis Repressor with Caspase recruitment domain (ARC). Hypertension. 2011;58:117 (Abstract 13). This study provides a novel mechanism for the cardioprotective action of low doses of MR antagonists during ischemia-reperfusion.
- Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci. 1983;80:6056–60. CrossRef
- Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268–75. CrossRef
- Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656–64. CrossRef
- Mihailidou, AS, Mardini M, Fraser T, et al. Agonist/antagonist activity of cortisol in cardiomyocyte mineralocorticoid receptors is determined by redox state. Presented at the International Aldosterone Conference, New Orleans, 2004.
- •• Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306–1312. This study provides direct evidence that during tissue damage, cortisol mimics the action of aldosterone in the heart. It is also shown that spironolactone acts as an inverse agonist, which may provide a mechanism for the beneficial effects of low doses of spironolactone in the RALES study. CrossRef
- Mihailidou AS, Buhagiar KA, Rasmussen HH. Na + influx and Na + -K + pump activation during short-term exposure of cardiac myocytes to aldosterone. Am J Physiol Cell Physiol. 1998;274:C175–81.
- Aldosterone in Heart Disease
Current Hypertension Reports
Volume 14, Issue 2 , pp 125-129
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Mineralocorticoid receptor
- Heart failure
- Primary aldosteronism
- Redox state
- Industry Sectors
- Author Affiliations
- 1. Department of Cardiology & Kolling Institute of Medical Research, Royal North Shore Hospital & University of Sydney, Pacific Highway, St. Leonards, Sydney, NSW, Australia, 2065